BR112015019794A8 - Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto - Google Patents

Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto

Info

Publication number
BR112015019794A8
BR112015019794A8 BR112015019794A BR112015019794A BR112015019794A8 BR 112015019794 A8 BR112015019794 A8 BR 112015019794A8 BR 112015019794 A BR112015019794 A BR 112015019794A BR 112015019794 A BR112015019794 A BR 112015019794A BR 112015019794 A8 BR112015019794 A8 BR 112015019794A8
Authority
BR
Brazil
Prior art keywords
compound
sphingosine
pharmaceutical composition
phosphate receptor
receptor agonist
Prior art date
Application number
BR112015019794A
Other languages
English (en)
Other versions
BR112015019794B1 (pt
BR112015019794A2 (pt
Inventor
Yup Paek Seung
Bae Lee Sung
Seong Park Deok
Hyung Lee Won
Original Assignee
Lg Life Sciences Ltd
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd, Lg Chemical Ltd filed Critical Lg Life Sciences Ltd
Publication of BR112015019794A2 publication Critical patent/BR112015019794A2/pt
Publication of BR112015019794A8 publication Critical patent/BR112015019794A8/pt
Publication of BR112015019794B1 publication Critical patent/BR112015019794B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, AGONISTA DO RECEPTOR DE ESFINGOSINA-1-FOSFATO, E, USO DE UM COMPOSTO A presente invenção refere-se a novos compostos da Fórmula 1 como agonistas do receptor de esfingosina-1-fosfato que podem ser eficazmente usados para o tratamento de doenças autoimunes, um método para preparar os mesmos e uma composição farmacêutica compreendendo os mesmos como um componente ativo. Os compostos de acordo com a presente invenção são eficazes nas doenças autoimunes extensivas e doenças inflamatórias crônicas incluindo a esclerose múltipla remitente-recorrente e também podem ser usados para tratar ou prevenir distúrbios de imunorregulagem.
BR112015019794-9A 2013-02-20 2014-02-19 Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto BR112015019794B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2013-0018293 2013-02-20
KR20130018293 2013-02-20
PCT/KR2014/001336 WO2014129796A1 (en) 2013-02-20 2014-02-19 Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent

Publications (3)

Publication Number Publication Date
BR112015019794A2 BR112015019794A2 (pt) 2017-07-18
BR112015019794A8 true BR112015019794A8 (pt) 2018-08-14
BR112015019794B1 BR112015019794B1 (pt) 2022-09-13

Family

ID=51391525

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019794-9A BR112015019794B1 (pt) 2013-02-20 2014-02-19 Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto

Country Status (17)

Country Link
US (1) US9540362B2 (pt)
EP (1) EP2958913B1 (pt)
JP (1) JP6294359B2 (pt)
KR (1) KR101939657B1 (pt)
CN (1) CN105051037B (pt)
AU (1) AU2014219575B2 (pt)
BR (1) BR112015019794B1 (pt)
DK (1) DK2958913T3 (pt)
ES (1) ES2698359T3 (pt)
HU (1) HUE039931T2 (pt)
MX (1) MX370032B (pt)
PL (1) PL2958913T3 (pt)
PT (1) PT2958913T (pt)
RU (1) RU2654483C2 (pt)
SI (1) SI2958913T1 (pt)
TW (1) TWI582073B (pt)
WO (1) WO2014129796A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
KR102644587B1 (ko) * 2015-12-24 2024-03-07 (주)아모레퍼시픽 유사 세라마이드 화합물 및 그 제조방법
EP3409658B9 (en) * 2016-01-29 2024-07-17 ONO Pharmaceutical Co., Ltd. Tetrahydronaphthalene derivative
US11192886B2 (en) * 2016-07-22 2021-12-07 Medshine Discovery Inc. S1P1 agonist and application thereof
CN114874209B (zh) 2017-03-07 2024-08-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
CN107382965A (zh) * 2017-08-14 2017-11-24 河南科技大学第附属医院 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法
KR101891051B1 (ko) * 2018-01-29 2018-08-31 주식회사 세종바이오메드 스핑고신-1-포스페이트 유사체 및 이의 합성 방법
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
AU2020206036A1 (en) * 2019-01-11 2021-08-05 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
CN110240537B (zh) * 2019-05-22 2022-06-21 成都阿奇生物医药科技有限公司 一种茚氧乙酸类化合物及其制备方法和用途
WO2021112461A1 (ko) 2019-12-03 2021-06-10 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물
KR20210073998A (ko) 2019-12-11 2021-06-21 주식회사 엘지화학 다발성 경화증 예방 또는 치료용 약제학적 조성물
TW202402285A (zh) * 2020-09-28 2024-01-16 南韓商Ｌｇ化學股份有限公司 神經鞘胺醇－１－磷酸受體促效劑的用途
WO2022065940A1 (ko) * 2020-09-28 2022-03-31 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 용도
EP4219443A4 (en) * 2020-10-13 2024-04-17 Lg Chem, Ltd. METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST
CN116323563A (zh) * 2020-10-13 2023-06-23 株式会社Lg化学 制备用于合成鞘氨醇-1-磷酸酯受体激动剂的中间体的方法
KR20220142378A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 고형 제제의 제조 방법
WO2022220610A1 (ko) 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법
KR20220142385A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 약제학적으로 허용되는 염 및 이의 결정형
KR20220142383A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 결정형
KR20220142388A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 신규한 제조방법
WO2022220599A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 결정형
CN117136183A (zh) * 2021-04-14 2023-11-28 株式会社Lg化学 制备鞘氨醇-1-磷酸酯受体激动剂的新方法
CN117203189A (zh) * 2021-04-14 2023-12-08 株式会社Lg化学 制备用于合成鞘氨醇-1-磷酸酯受体激动剂的中间体的方法
WO2022220597A1 (ko) 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 결정형
KR20220142379A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 습식과립법에 의한 스핑고신-1-인산 수용체 효능제를 포함하는 경구용 고형 제제의 제조 방법
CN117136181A (zh) 2021-04-14 2023-11-28 株式会社Lg化学 用于合成鞘氨醇-1-磷酸酯受体激动剂的中间体的制备方法
CN117202893A (zh) * 2021-04-14 2023-12-08 株式会社Lg化学 包含鞘氨醇-1-磷酸受体激动剂的可直接压缩的药物组合物
KR20220142377A (ko) 2021-04-14 2022-10-21 주식회사 엘지화학 입도가 조절된 스핑고신-1-인산 수용체 효능제를 포함하는 약제학적 조성물
WO2022220598A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 결정형

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
WO2004022551A1 (ja) 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited フランまたはチオフェン誘導体およびその医薬用途
WO2004063155A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
WO2004092116A1 (en) 2003-04-10 2004-10-28 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
JP4318087B2 (ja) 2004-12-13 2009-08-19 小野薬品工業株式会社 アミノカルボン酸誘導体およびその医薬用途
CN101146796A (zh) 2005-01-26 2008-03-19 先灵公司 作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
US20090082349A1 (en) 2006-03-02 2009-03-26 Dashyant Dhanak Thiazolones for use as pi3 kinase inhibitors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
EP2099741A2 (en) 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
CA2695114A1 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
US8153103B2 (en) 2008-07-01 2012-04-10 Board Of Regents, The University Of Texas System Conjugates of photo-activatable dyes
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
WO2010069949A1 (en) 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
US20100174539A1 (en) 2009-01-06 2010-07-08 Qualcomm Incorporated Method and apparatus for vector quantization codebook search
KR20100092909A (ko) 2009-02-13 2010-08-23 주식회사 엘지생명과학 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
EP2241558A1 (en) 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
TW201107302A (en) 2009-06-26 2011-03-01 Glaxo Group Ltd Compounds
BR112012011431A8 (pt) * 2009-11-13 2017-12-26 Receptos Llc Moduladores heterocíclicos seletivos de receptor de esfingosina 1 fosfato
EP2498611B1 (en) 2009-11-13 2018-01-10 Celgene International II Sàrl Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
NZ599966A (en) * 2009-11-24 2014-09-26 Allergan Inc Novel compounds as receptor modulators with therapeutic utility
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
CN103380112A (zh) * 2010-11-24 2013-10-30 阿勒根公司 作为s1p受体调节剂的吲哚衍生物
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物

Also Published As

Publication number Publication date
HUE039931T2 (hu) 2019-02-28
BR112015019794B1 (pt) 2022-09-13
MX370032B (es) 2019-11-28
RU2015139594A (ru) 2017-03-27
PT2958913T (pt) 2018-12-03
US9540362B2 (en) 2017-01-10
WO2014129796A1 (en) 2014-08-28
AU2014219575A1 (en) 2015-08-20
TW201444794A (zh) 2014-12-01
TWI582073B (zh) 2017-05-11
ES2698359T3 (es) 2019-02-04
CN105051037A (zh) 2015-11-11
CN105051037B (zh) 2018-05-18
PL2958913T3 (pl) 2019-03-29
KR20140104376A (ko) 2014-08-28
KR101939657B1 (ko) 2019-01-17
JP6294359B2 (ja) 2018-03-14
MX2015009986A (es) 2015-10-05
EP2958913B1 (en) 2018-10-03
RU2654483C2 (ru) 2018-05-21
DK2958913T3 (en) 2018-11-05
SI2958913T1 (sl) 2018-12-31
BR112015019794A2 (pt) 2017-07-18
JP2016513126A (ja) 2016-05-12
US20150376173A1 (en) 2015-12-31
AU2014219575B2 (en) 2017-07-06
EP2958913A4 (en) 2016-10-05
EP2958913A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
BR112015019794A8 (pt) Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
BR112015022566A2 (pt) composto e composição farmacêutica
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112018067923A2 (pt) métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
BR112015022044A2 (pt) um método de proporcionar neutroproteção ocular
BR112018004719A2 (pt) composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/02/2014, OBSERVADAS AS CONDICOES LEGAIS